You are here
P2D, INC
UEI: KX3EAX2JEMV8
# of Employees: 2
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Rho GTPase inhibitors for refrigerated platelet storage
Amount: $224,700.00ABSTRACT The use of platelet transfusions has increased dramatically since 1980s, but a safe, long-term platelet storage method remains missing. Current practice has platelets stored at 20 to 24 C aft ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
LIVERCHIP- A diagnostic tool for genetic liver diseases
Amount: $1,178,516.00DESCRIPTION provided by applicant Genetic mutations are known to cause acute and chronic liver diseases and are being increasingly recognized as drivers of phenotype severity As a group these di ...
SBIRPhase II2014Department of Health and Human Services National Institutes of Health -
Coronary Post-Dilatation Catheter
Amount: $395,476.00DESCRIPTION (provided by applicant): The goal of this proposal is to develop tumor necrosis factor (TNF )-inhibiting compounds as neuroprotectant drugs for treating Alzheimer's disease (AD). Cu ...
SBIRPhase I2013Department of Health and Human Services National Institutes of Health -
Pharmacological rejuvenation of aged hematopoietic stem cells.
Amount: $361,403.00DESCRIPTION (provided by applicant): The demographic development in most Western countries predicts that age-associated diseases and their prevention will become an important social, economic and med ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
A Novel Small molecule TNF?? inhibitor as a disease-modifying AD drug treatment.
Amount: $390,959.00DESCRIPTION (provided by applicant): The goal of this application is to develop tumor necrosis factor (TNF )-inhibiting compounds as neuroprotectant drugs for treating Alzheimer's disease (AD). ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
JAUNDICE NEXT: A diagnostic tool for cholestatic liver disease.
Amount: $344,780.00DESCRIPTION (provided by applicant): Cholestasis (or pathologic jaundice) is the most common sign of liver disease in children and often results from mutations in genes that play a critical role in bi ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Improving hematopoietic stem cell mobilization by the EGFR inhibitor Erlotinib
Amount: $390,255.00DESCRIPTION (provided by applicant): Hematopoietic stem and progenitor cell (HSPC) transplants are a first-line treatment for multiple forms of cancer. The current standard of care for obtaining HSPCs ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
A rapid microfluidic P.O.C CNS biomarker platform to predict delayed HICP onset.
Amount: $348,668.00DESCRIPTION (provided by applicant): The proposed SBIR program aims to develop a rapid point-of-care (POC) prognosticative assay device that provides clinically actionable data to predict onset of hig ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
PD2005: A CNS active DAT inhibitor for improving cognitive deficits in traumatic
Amount: $263,333.00DESCRIPTION (provided by applicant): The purpose of the present SBIR Phase 1 feasibility study is to assess the efficacy of our selective dopamine (DA) transport inhibitor PD2005 in improving cognitiv ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
Phase 2 Selective DAT inhibitor for treatment of Obesity.
Amount: $1,510,798.00DESCRIPTION (provided by applicant): PD2007 is a selective DAT inhibitor that P2D Bioscience (P2D) is developing for the treatment of obesity. PD2007 is an analog of benztropine (Cogentin) a non-Sched ...
SBIRPhase II2011Department of Health and Human Services National Institutes of Health
